0.8506
Schlusskurs vom Vortag:
$0.90
Offen:
$0.91
24-Stunden-Volumen:
280.07K
Relative Volume:
1.07
Marktkapitalisierung:
$107.44M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-70.78M
KGV:
-1.5189
EPS:
-0.56
Netto-Cashflow:
$-61.27M
1W Leistung:
-3.63%
1M Leistung:
+20.31%
6M Leistung:
+15.02%
1J Leistung:
-68.61%
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
Firmenname
Nautilus Biotechnology Inc
Sektor
Branche
Telefon
206-333-2001
Adresse
2701 EASTLAKE AVE EAST, SEATTLE
Vergleichen Sie NAUT mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
NAUT
Nautilus Biotechnology Inc
|
0.8506 | 113.67M | 0 | -70.78M | -61.27M | -0.56 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-12-05 | Herabstufung | Goldman | Neutral → Sell |
2024-06-27 | Eingeleitet | Guggenheim | Buy |
2024-06-03 | Fortgesetzt | Jefferies | Hold |
2022-01-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
2021-11-02 | Eingeleitet | Cowen | Outperform |
2021-08-04 | Eingeleitet | Goldman | Neutral |
2021-07-13 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Nautilus Biotechnology Inc Aktie (NAUT) Neueste Nachrichten
Weiss Ratings Reaffirms Sell (D-) Rating for Nautilus Biotechnology (NASDAQ:NAUT) - MarketBeat
Will Nautilus Biotechnology Inc. price bounce be sustainableJuly 2025 Fed Impact & Accurate Buy Signal Notifications - newser.com
Should you hold or exit Nautilus Biotechnology Inc. now2025 Analyst Calls & Low Volatility Stock Suggestions - newser.com
Live market analysis of Nautilus Biotechnology Inc.Market Trend Review & Reliable Entry Point Alerts - newser.com
Published on: 2025-10-09 04:18:13 - newser.com
Will Nautilus Biotechnology Inc. see short term momentumFed Meeting & Reliable Price Action Trade Plans - newser.com
Is Nautilus Biotechnology Inc a good long term investmentMarket Entry Points & Smart Beta Strategies That Actually Work - earlytimes.in
Nautilus Biotechnology to Announce Third Quarter 2025 Financial Results on October 28, 2025 - GlobeNewswire
Nautilus Biotechnology, Inc. to Announce Third Quarter 2025 Financial Results on October 28, 2025 - Quiver Quantitative
Nautilus Biotechnology to Participate in Upcoming September Investor Conferences - 富途牛牛
What institutional flow reveals about Nautilus Biotechnology Inc.2025 Institutional Moves & Community Consensus Picks - newser.com
Nautilus Biotechnology Inc. recovery potential after sell offJuly 2025 Fed Impact & Free Community Supported Trade Ideas - newser.com
Is now a turning point for Nautilus Biotechnology Inc.July 2025 Catalysts & High Accuracy Swing Trade Signals - newser.com
How sentiment analysis helps forecast Nautilus Biotechnology Inc.Weekly Stock Summary & Verified Entry Point Signals - newser.com
Nautilus Biotechnology Inc. stock daily chart insightsWeekly Profit Summary & Long Hold Capital Preservation Tips - newser.com
Detecting price anomalies in Nautilus Biotechnology Inc. with AI2025 Top Gainers & Fast Gaining Stock Reports - newser.com
Analyzing Nautilus Biotechnology Inc. with multi timeframe chartsJuly 2025 Opening Moves & Intraday High Probability Alerts - newser.com
What analysts say about Nautilus Biotechnology Inc stockFlag and Pennant Patterns & Exceptional Growth Investment - earlytimes.in
Goldman Sachs Group Inc. Has $148,000 Stock Position in Nautilus Biotechnology, Inc. $NAUT - Defense World
Nautilus Biotechnology (NASDAQ:NAUT) Trading Down 3.2% – Here’s Why - Defense World
Nautilus Biotechnology (NASDAQ:NAUT) Trading Down 3.2%Here's Why - MarketBeat
Price momentum metrics for Nautilus Biotechnology Inc. explained2025 Market Trends & Risk Adjusted Swing Trade Ideas - newser.com
Finanzdaten der Nautilus Biotechnology Inc-Aktie (NAUT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nautilus Biotechnology Inc-Aktie (NAUT) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Patel Sujal M | CEO, President, and Secretary |
Sep 08 '25 |
Buy |
0.68 |
83,500 |
57,031 |
10,341,721 |
Murphy Matthew B. | General Counsel |
Sep 04 '25 |
Buy |
0.64 |
20,000 |
12,858 |
74,140 |
Mowry Anna | CFO and Treasurer |
May 29 '25 |
Buy |
0.77 |
15,000 |
11,488 |
83,000 |
Mallick Parag | Chief Scientist |
May 08 '25 |
Buy |
0.73 |
12,000 |
8,788 |
20,491,892 |
Mallick Parag | Chief Scientist |
May 12 '25 |
Buy |
0.73 |
1,500 |
1,098 |
20,493,392 |
Patel Sujal M | CEO, President, and Secretary |
Mar 19 '25 |
Buy |
0.99 |
53,300 |
53,028 |
10,117,788 |
Patel Sujal M | CEO, President, and Secretary |
Mar 20 '25 |
Buy |
1.00 |
23,933 |
23,890 |
10,141,721 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):